BFRI
Biofrontera just sent Ameluz back to the FDA
Biofrontera says it has filed a supplemental New Drug Application for Ameluz, aiming to expand the drug’s approved use in combination with photodynamic therapy for actinic keratoses. In plain English: the company is trying to get the label widened so the same product can be used in a bigger corner of the market.
Why investors should care
This is not a sales print or an approval yet — it’s the paperwork stage. But label expansions can matter a lot for small biopharma names because they can turn an existing asset into a bigger revenue engine without needing a brand-new drug.
The fine print
- Ameluz is already approved, and Biofrontera wants the FDA to broaden how it can be used
- The target condition is actinic keratoses, a common precancerous skin lesion
- The upside is straightforward: more approved use cases can mean more prescribing flexibility and more commercial runway
Big picture: Biofrontera is trying to squeeze more juice out of an existing asset, and if the FDA eventually says yes, that could be a meaningful catalyst for a small-cap biotech that doesn’t exactly have spare blockbuster hits lying around.